MIAMI
BEACH, Fla., July 26,
2024 /PRNewswire/ -- Immorta Bio Inc, a science-based
longevity company dedicated to treating "Diseases of Aging and
Aging as a Disease™" with personalized cellular solutions, today
announced the filing of an Investigational New Drug (IND)
application with the Food and Drug Administration (FDA).
The IND, which was granted #30745, is to initiate a clinical
trial to evaluate safety, immunogenicity, and efficacy signals of
SenoVax in patients with advanced non-small cell lung cancer. The
trial will recruit patients who have failed standard therapies and
will comprise of three patient groups receiving increasing doses of
SenoVax.
SenoVax leverages dendritic cell technology to augment the
natural ability of the immune system to clear senescent
cells. These cells, referred to as "zombie cells", are known
to accelerate the process of aging. In the context of cancer,
senescent cells have been demonstrated to surround tumors and to
provide a protective element that "hides" cancers from immune
attack1,2,3,4. Previous studies by Immorta Bio have
shown that SenoVax can reduce growth of lung cancer in animal
models and can induce immune responses that selectively kill
senescent cells in the laboratory.
"To our knowledge, this is the first clinical candidate to push
the immune system to attack not the cancer itself, but the cells
protecting it," said Thomas Ichim,
PhD, President and Chief Scientific Officer of Immorta Bio. "In
contrast to cancer, which mutates in a very rapid manner, senescent
cells surrounding the tumor do not mutate, thus making them a more
attractive therapeutic target. While the primary aim of the study
is not to investigate systemic effects, it will be of significant
interest to observe any additional regenerative benefits of
the SenoVax therapy, beyond its impact on tumor size
reduction."
Studies suggest that reducing the number of senescent cells
using small molecule approaches reduces adverse effects of the
aging process, such as declines in physical5 and mental
function6,7. In addition, it has been reported that
reduction of senescent cells increases therapeutic efficacy of
chemotherapy8, radiation therapy9, and
immunotherapy10,11. Based on recent findings, the
Company hypothesizes that immune mediated clearance of senescent
cells is a more attractive approach as compared to small molecules
since one of the natural functions of the immune system is to clear
these cells.
"I am thankful for our team, and our clinical and scientific
collaborators that have taken this promising laboratory technology
and have advanced it into a candidate for clinical assessment,"
said Boris Reznik, PhD, Chairman and
CEO of Immorta Bio. Our Senolytic Immunotherapy has the potential
to be valuable not only as a monotherapy, but also as an adjuvant
to numerous oncological treatments that are currently in the
clinic."
About SenoVax
SenoVax is an autologous polyvalent cellular therapeutic that
induces immune responses against senescent cells. It is produced by
extracting a skin biopsy and creating autologous senescent cells
in vitro using a proprietary mechanism. These "accelerated
senescent" cells are used as an antigenic source to pulse patient
derived dendritic cells generated ex vivo. SenoVax combines
the potency of dendritic cell immunotherapy, with the novel target
of killing tumor associated senescent cells. Preclinical studies
have demonstrated SenoVax can reduce growth of lung cancer in
animal models and can induce immune responses that selectively kill
senescent cells in the laboratory.
About Immorta Bio
Immorta Bio is a longevity-focused biotechnology company
developing efficient and practical personalized cellular
therapeutic platforms focused on Treating Diseases of Aging and
Treating Aging as Disease™. Our therapeutic candidates target unmet
need indications across various organ systems. By developing
personalized cellular therapies for aging-related diseases, we have
the potential to significantly extend our patients' healthy
longevity.
For more information, please visit the Immorta Bio website
at https://www.immortabio.com or find them on X
at https://twitter.com/ImmortaBio.
Company Contact
Dr. Boris Reznik
Immorta Bio
https://www.immortabio.com
+1 305-632-2939
@immortabio
Media Contacts
David
Schull
Russo Partners, LLC
380933@email4pr.com
1
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789819/
2
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4899869/
3
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547655/
4 https://pubmed.ncbi.nlm.nih.gov/25263564
5
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6082705/
6
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833137/
7
https://onlinelibrary.wiley.com/doi/10.1111/joim.13141
8
https://link.springer.com/article/10.1186/s43556-023-00116-4
9 https://elifesciences.org/articles/75492
10
https://www.nature.com/articles/s41467-024-46769-9#:~:text=Elimination%20of%20these%20myeloid%20cells,the%20effectiveness%20of%20cancer%20immunotherapies.
11 https://pubmed.ncbi.nlm.nih.gov/38794820/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/immorta-bio-files-investigational-new-drug-application-for-first-in-class-senolytic-immunotherapy-senovax-for-treatment-of-advanced-lung-cancer-302207491.html
SOURCE Immorta Bio, Inc